<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Targeted therapy</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Montara secures seed funding for binary brain pharmacology</title>
      <description>
        <![CDATA[Montara Therapeutics Inc. has received $8 million seed financing from several investors to further its development of its ’binary pharmacology’ for diseases of the brain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711054</guid>
      <pubDate>Wed, 31 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711054-montara-secures-seed-funding-for-binary-brain-pharmacology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Blood-Brain-Barrier-Illustration.webp?t=1678203491" type="image/png" medium="image" fileSize="856287">
        <media:title type="plain">Illustration of brain in head highlighting the blood-brain barier.</media:title>
      </media:content>
    </item>
    <item>
      <title>Confo financing will in part bring two compounds to IND</title>
      <description>
        <![CDATA[G protein-coupled receptor (GPCR) drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it continues to turn the handle on its technology platform to generate more compounds for partnering.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711005</guid>
      <pubDate>Mon, 29 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711005-confo-financing-will-in-part-bring-two-compounds-to-ind</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Piggy-bank-filled-with-dollar-coins.webp?t=1722265123" type="image/jpeg" medium="image" fileSize="193287">
        <media:title type="plain">Piggy bank filled with dollar coins</media:title>
      </media:content>
    </item>
    <item>
      <title>Glis2 targeting suppresses cyst formation in polycystic kidney disease models</title>
      <description>
        <![CDATA[Researchers from Yale School of Medicine, Ionis Pharmaceuticals Inc. and the National Institutes of Health have published data from a study that aimed to identify the signaling pathways involved in cilia-dependent cyst activation (CDCA) in autosomal dominant polycystic kidney disease (ADPKD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/708529</guid>
      <pubDate>Thu, 16 May 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708529-glis2-targeting-suppresses-cyst-formation-in-polycystic-kidney-disease-models</link>
    </item>
    <item>
      <title>α5 integrin is therapeutic target in amyotrophic lateral sclerosis</title>
      <description>
        <![CDATA[Researchers from Oregon Health and Science University presented data from a study that aimed to identify and validate potential new therapeutic targets for the treatment of amyotrophic lateral sclerosis (ALS). Systems immunology analysis utilizing mass cytometry (CyTOF) was used to assess α5 integrin expression in 78,293 single cells, including 21,250 CD45+/CD11b+ myeloid cells from CNS of superoxide dismutase-1 (SOD) G93A mouse model of ALS (SOD1G93A).]]>
      </description>
      <guid>http://www.bioworld.com/articles/699749</guid>
      <pubDate>Tue, 08 Aug 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699749-5-integrin-is-therapeutic-target-in-amyotrophic-lateral-sclerosis</link>
    </item>
    <item>
      <title>ESMO TAT: Tumor therapies find new ways into the brain, by finesse or force</title>
      <description>
        <![CDATA[Whether as primary tumors or metastases, brain tumors remain stubbornly intractable to the progress that has occurred in many other tumor types. As Igor Vivanco, who is a senior lecturer in the Institute of Pharmaceutical Science at King’s College London, noted in his talk at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) meeting in Paris this week, the last win in glioblastoma was the addition of temozolomide to the radiotherapy standard of care in 2005. And temozolomide’s benefit is measured in months, not years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694852</guid>
      <pubDate>Tue, 07 Mar 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694852-esmo-tat-tumor-therapies-find-new-ways-into-the-brain-by-finesse-or-force</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Blood-Brain-Barrier-Illustration.webp?t=1678203491" type="image/png" medium="image" fileSize="856287">
        <media:title type="plain">Illustration of brain in head highlighting the blood-brain barier.</media:title>
      </media:content>
    </item>
    <item>
      <title>Ifi27l2a identified as new therapeutic target to reduce brain injury in stroke</title>
      <description>
        <![CDATA[Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694522</guid>
      <pubDate>Thu, 23 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694522-ifi27l2a-identified-as-new-therapeutic-target-to-reduce-brain-injury-in-stroke</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-stroke.webp?t=1589299060" type="image/png" medium="image" fileSize="380269">
        <media:title type="plain">Cross-section of brain </media:title>
      </media:content>
    </item>
    <item>
      <title>VGLL3 as novel therapeutic target in fibrosis</title>
      <description>
        <![CDATA[While it is known that differentiated myofibroblasts produce excessive collagens, which accumulate in tissues and cause hardening, the mechanisms involved in these processes are largely unknown. In a recent study, Kyushu University scientists aimed to assess the molecular mechanisms by which matrix stiffness increases fibrosis-related gene expression in myofibroblasts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694437</guid>
      <pubDate>Tue, 21 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694437-vgll3-as-novel-therapeutic-target-in-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-structures-microscope.webp?t=1682529172" type="image/png" medium="image" fileSize="579163">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>pCTS-L as new therapeutic target in potentially lethal sepsis</title>
      <description>
        <![CDATA[Cathepsin L (CTS-L) is a lysosomal enzyme responsible for degrading endocytosed proteins to generate immunogenic antigens for adaptive immunities. In the current study, researchers reported data from a study that aimed to assess the potential of targeting procathepsin L (pCTS-L) as a potential therapeutic strategy against sepsis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694277</guid>
      <pubDate>Wed, 15 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694277-pcts-l-as-new-therapeutic-target-in-potentially-lethal-sepsis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/sepsis-bacteria-blood.webp?t=1745260750" type="image/jpeg" medium="image" fileSize="307255">
        <media:title type="plain">Blood cells and bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>SULF1 knockdown seen to modulate TNBC metastatic potential</title>
      <description>
        <![CDATA[Triple-negative breast cancer (TNBC) still remains as one of the most aggressive breast cancer types among women, with high metastatic potential and ability to shift towards epithelial-mesenchymal transition (EMT).]]>
      </description>
      <guid>http://www.bioworld.com/articles/694276</guid>
      <pubDate>Wed, 15 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694276-sulf1-knockdown-seen-to-modulate-tnbc-metastatic-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NCI-Dividing-Breast-Cancer-Cell.webp?t=1671722892" type="image/png" medium="image" fileSize="664078">
        <media:title type="plain">Dividing breast cancer cell.</media:title>
        <media:description type="plain">A triple-negative breast cancer cell (MDA-MB-231) in metaphase during cell division. Tubulin in red; mitochondria in green; chromosomes in blue. Credit: Wei Qian, University of Pittsburgh Cancer Institute/National Cancer Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>IL-2RG blockade as a therapeutic strategy for prevention and treatment of T-cell-mediated disease</title>
      <description>
        <![CDATA[The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693889</guid>
      <pubDate>Fri, 03 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693889-il-2rg-blockade-as-a-therapeutic-strategy-for-prevention-and-treatment-of-t-cell-mediated-disease</link>
    </item>
    <item>
      <title>Novel organo-arsenic compound suppresses osteosarcoma growth by inhibiting PDK-1</title>
      <description>
        <![CDATA[Researchers from Zhongnan Hospital of Wuhan University reported data from a study that aimed to evaluate the therapeutic efficiency of organic arsenic compounds for the treatment of osteosarcoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693876</guid>
      <pubDate>Thu, 02 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693876-novel-organo-arsenic-compound-suppresses-osteosarcoma-growth-by-inhibiting-pdk-1</link>
    </item>
    <item>
      <title>CREB1 inhibition reverses mammary tumor growth caused by Cullin-5 deficiency</title>
      <description>
        <![CDATA[Breast cancer-associated gene 1 (BRCA1) is a critical tumor suppressor in breast cancer, and BRCA1 deficiency impairs DNA damage repair, leading to DNA damage accumulation and subsequent genetic alterations that result in the onset of breast cancer. In the current study, researchers from the University of Macau aimed to identify the potential factors that may participate in BRCA1-associated tumorigenesis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693777</guid>
      <pubDate>Tue, 31 Jan 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693777-creb1-inhibition-reverses-mammary-tumor-growth-caused-by-cullin-5-deficiency</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-illustration.webp?t=1755012743" type="image/jpeg" medium="image" fileSize="458149">
        <media:title type="plain">Breast cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CLDN1 is a therapeutic target in primary sclerosing cholangitis</title>
      <description>
        <![CDATA[Primary sclerosing cholangitis (PSC) is a disease affecting the bile ducts that can lead to end-stage liver disease and cholangiocarcinoma. Patients with this disease lack therapeutic treatment other than liver transplantation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691802</guid>
      <pubDate>Tue, 22 Nov 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691802-cldn1-is-a-therapeutic-target-in-primary-sclerosing-cholangitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-gallbladder-bile-ducts-anatomy.webp?t=1669131393" type="image/png" medium="image" fileSize="718435">
        <media:title type="plain">Liver anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CACNB3 as novel therapeutic target in mesial temporal lobe epilepsy</title>
      <description>
        <![CDATA[Investigators at the University of Copenhagen and affiliated organizations presented data from a study that aimed to validate differentially expressed genes (DEGs) in mesial temporal lobe epilepsy (mTLE) as potential new targets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691678</guid>
      <pubDate>Thu, 17 Nov 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691678-cacnb3-as-novel-therapeutic-target-in-mesial-temporal-lobe-epilepsy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Epilepsy-illustration.webp?t=1600196724" type="image/png" medium="image" fileSize="542753">
        <media:title type="plain">Brain and encephalography</media:title>
      </media:content>
    </item>
    <item>
      <title>Targeting Stk4 alters Treg cell function relevant to cancer immunotherapy and autoimmunity</title>
      <description>
        <![CDATA[Regulatory T (Treg) cells play a key role in peripheral tolerance and they prevent immune dysregulation as well as promote tissue...]]>
      </description>
      <guid>http://www.bioworld.com/articles/690823</guid>
      <pubDate>Wed, 26 Oct 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690823-targeting-stk4-alters-treg-cell-function-relevant-to-cancer-immunotherapy-and-autoimmunity</link>
    </item>
    <item>
      <title>BATF as key epigenetic regulator of human Treg cells in the TME</title>
      <description>
        <![CDATA[Regulatory T (Treg) cells represent promising targets in cancer immunotherapy...]]>
      </description>
      <guid>http://www.bioworld.com/articles/690717</guid>
      <pubDate>Thu, 20 Oct 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690717-batf-as-key-epigenetic-regulator-of-human-treg-cells-in-the-tme</link>
    </item>
    <item>
      <title>Serotonin-targeting agents as potential therapeutic option for long-term control of tumors</title>
      <description>
        <![CDATA[Researchers from University Hospital and University of Zürich aimed to assess the effects of serotonin on the tumor microenvironment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690216</guid>
      <pubDate>Tue, 04 Oct 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690216-serotonin-targeting-agents-as-potential-therapeutic-option-for-long-term-control-of-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Serotonin-molecule-stucture.webp?t=1664899355" type="image/png" medium="image" fileSize="337254">
        <media:title type="plain">Serotonin molecule</media:title>
      </media:content>
    </item>
    <item>
      <title>α-MSH, a newly identified regulator of glycemia in human physiology</title>
      <description>
        <![CDATA[Researchers from University College Dublin and affiliated organizations presented data from a study that aimed to assess the role of α-melanocyte-stimulatory hormone (α-MSH) in diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690044</guid>
      <pubDate>Wed, 28 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690044-msh-a-newly-identified-regulator-of-glycemia-in-human-physiology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Diabetes-blood-insulin-glucose.webp?t=1663859296" type="image/png" medium="image" fileSize="1187639">
        <media:title type="plain">Concept art for blood sugar.</media:title>
      </media:content>
    </item>
    <item>
      <title>IL-27 gene signature is enriched for IFN‑stimulated genes associated with cancer therapy resistance</title>
      <description>
        <![CDATA[Scientists at Surface Oncology Inc. described data from a study that aimed to evaluate the role of IL-27, a heterodimeric cytokine that plays a role in controlling the intensity and duration of immune system responses, in cancer therapy resistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689998</guid>
      <pubDate>Tue, 27 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689998-il-27-gene-signature-is-enriched-for-ifnstimulated-genes-associated-with-cancer-therapy-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-and-Cancer-immunotherapy.webp?t=1630448514" type="image/png" medium="image" fileSize="480994">
        <media:title type="plain">Cancer cell and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Targeting BMPR2 is an approach to treat lung cancer</title>
      <description>
        <![CDATA[Researchers have designed a 3D model of lung cancer that is composed of bronchial epithelial, fibroblasts, epithelial, lung adenocarcinoma and immune cells grown in different layers in a matrigel.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689895</guid>
      <pubDate>Thu, 22 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689895-targeting-bmpr2-is-an-approach-to-treat-lung-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-3d-illo.webp?t=1745257422" type="image/jpeg" medium="image" fileSize="363200">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Discovery of novel KRAS G12C inhibitor with promising in vivo efficacy and safety</title>
      <description>
        <![CDATA[Researchers from Sun Yat-sen University, Southern Medical University and Gannan Medical University reported the discovery of novel quinazoline-based KRAS G12C inhibitors as potential anticancer agents.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689855</guid>
      <pubDate>Wed, 21 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689855-discovery-of-novel-kras-g12c-inhibitor-with-promising-in-vivo-efficacy-and-safety</link>
    </item>
    <item>
      <title>TYRA-300 retains potency in presence of gatekeeper resistance mutation </title>
      <description>
        <![CDATA[Researchers from Tyra Biosciences Inc. presented a novel FGFR3-selective inhibitor agnostic to the gatekeeper mutation, named TYRA-300.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689854</guid>
      <pubDate>Wed, 21 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689854-tyra-300-retains-potency-in-presence-of-gatekeeper-resistance-mutation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells1.webp?t=1633723840" type="image/png" medium="image" fileSize="463145">
        <media:title type="plain">Cancer cells</media:title>
      </media:content>
    </item>
    <item>
      <title>EED inhibitor HJM-353 shows antitumor activity in preclinical models of cancer</title>
      <description>
        <![CDATA[Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/689763</guid>
      <pubDate>Mon, 19 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689763-eed-inhibitor-hjm-353-shows-antitumor-activity-in-preclinical-models-of-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>PARP-1 decoy OX-413 promotes tumor cell metabolic exhaustion</title>
      <description>
        <![CDATA[Poly (ADP-ribose) polymerase (PARP) inhibitors promote significant anticancer effects against homologous recombination-defective (HRD) tumors but have limited efficacy against homologous recombination proficient (HRP) cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689733</guid>
      <pubDate>Fri, 16 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689733-parp-1-decoy-ox-413-promotes-tumor-cell-metabolic-exhaustion</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NCI-Cancer-Cells.webp?t=1663340011" type="image/png" medium="image" fileSize="2149620">
        <media:title type="plain">Cancer cells.</media:title>
        <media:description type="plain">Cancer cells in culture from human connective tissue, illuminated by darkfield amplified contrast, at a magnification of 500x. Credit: Cecil Fox, National Cancer Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>CYT-303 antibody promotes tumor NK-cell infiltration in HCC model</title>
      <description>
        <![CDATA[GPC3 is an oncofetal antigen highly expressed in hepatocellular carcinoma (HCC) but minimally expressed in adult normal tissues, except the placenta. Cytovia Therapeutics Inc. has presented preclinical data on CYT-303, a bispecific natural killer (NK) engager targeting NK cell-activating receptor NKp46 and GPC3 expressed in tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689731</guid>
      <pubDate>Fri, 16 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689731-cyt-303-antibody-promotes-tumor-nk-cell-infiltration-in-hcc-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Human-NK-cell.webp?t=1602864300" type="image/png" medium="image" fileSize="287211">
        <media:title type="plain">Human NK cell</media:title>
        <media:description type="plain">Human natural killer cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>PRAME-targeting IMA-402 TCER shows promise for treating solid tumors</title>
      <description>
        <![CDATA[Researchers from Immatics Biotechnologies GmbH have developed bispecific T-cell engaging receptor (TCER) molecules consisting of an affinity maturated TCR, a humanized T cell-recruiting antibody and an Fc-part conferring half-life extension and favorable stability characteristics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689689</guid>
      <pubDate>Thu, 15 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689689-prame-targeting-ima-402-tcer-shows-promise-for-treating-solid-tumors</link>
    </item>
    <item>
      <title>Arginase inhibitor OATD-02 shows promise in cancer treatment</title>
      <description>
        <![CDATA[Arginases play key roles in metabolic pathways. Arginase 1 (ARG1) is expressed by myeloid cells in the tumor microenvironment and suppresses the functioning of T and NK cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689676</guid>
      <pubDate>Thu, 15 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689676-arginase-inhibitor-oatd-02-shows-promise-in-cancer-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-cell.webp?t=1588881270" type="image/png" medium="image" fileSize="329861">
        <media:title type="plain">Cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Novartis presents new RET inhibitors for lung adenocarcinoma</title>
      <description>
        <![CDATA[Proto-oncogene tyrosine-protein kinase receptor Ret is a widely expressed oncogene and chromosomal rearrangements involving RET lead to fusion genes and RET kinase activation, which occur in lung cancer in about in 2% of cases of non-small cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689637</guid>
      <pubDate>Wed, 14 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689637-novartis-presents-new-ret-inhibitors-for-lung-adenocarcinoma</link>
    </item>
    <item>
      <title>BI-4142 and BI-1622 show efficacy against HER2 exon 20 insertion-driven tumors, while preserving EGFR wt signaling</title>
      <description>
        <![CDATA[Boehringer Ingelheim Pharma GmbH & Co KG has presented data on the identification of several potent and selective tyrosine kinase inhibitors (TKIs) of HER2 that are highly active against its oncogenic exon 20 YVMA insertion mutant (HER2 YVMA), which is the most prevalent HER2 exon 20 mutation in non-small-cell lung cancer (NSCLC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/689628</guid>
      <pubDate>Wed, 14 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689628-bi-4142-and-bi-1622-show-efficacy-against-her2-exon-20-insertion-driven-tumors-while-preserving-egfr-wt-signaling</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/lung-cancer.webp?t=1588881354" type="image/png" medium="image" fileSize="422296">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Targeting ApoB100 rescues motor neuron degeneration in ALS</title>
      <description>
        <![CDATA[Amyotrophic lateral sclerosis (ALS) is a progressive disease characterized by upper and lower motor neuron degeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689578</guid>
      <pubDate>Tue, 13 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689578-targeting-apob100-rescues-motor-neuron-degeneration-in-als</link>
    </item>
  </channel>
</rss>
